comparemela.com

Latest Breaking News On - Visit accordbiopharma - Page 1 : comparemela.com

Henlius Announces U S FDA Acceptance of Biologics License Application for Proposed Biosimilar Trastuzumab HLX02

/PRNewswire/ Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License.

United statesUnited kingdomSaudi arabiaJason zhuPrnewswire shanghai henlius biotech incJacobson groupAccord biopharma incEuropean commissionDrug administrationIntas pharmaceuticals ltdEuropean medicines agencyNational medical products administrationHenlius biotechBiologics license applicationAccord biopharmaXuhui facility

Accord BioPharma Announces AccordConnects Inventory Management System for Hospitals and Healthcare Practices

/PRNewswire/ Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care.

Nuvan dassanaikeIntas pharmaceuticals ltdIntas pharmaceuticalsAccord biopharmaApp storeGoogle playMarketing strategyVisit accordbiopharmaVice president digitalHealth care amp hospitalsMedical pharmaceuticalsMobile entertainmentComputer amp electronicsComputer softwareMultimedia amp internetNew products amp services

Accord BioPharma, in Partnership with Foresee Pharmaceuticals, Launches CAMCEVI™ (Leuprolide) Injection Emulsion in the U S for the Treatment of Advanced Prostate Cancer in Adults

/PRNewswire/ Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd. focused on development of oncology, immunology, and critical care.

T ai peiBen chienChrys kokinoBinish chudgarNuvan dassanaikePharmaceuticals onPharmaceuticals co ltdIntas pharmaceuticals ltdIntas pharmaceuticalsDrug administrationTaipei exchangeAccord biopharmaNew drug applicationForesee pharmaceuticalsStabilized injectable formulationAccord healthcare

Accord BioPharma Announces U S Launch for CAMCEVI™ (Leuprolide) Injection Emulsion for the Treatment of Advanced Prostate Cancer in Adults

/PRNewswire/ Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd. focused on development of oncology, immunology, and critical care.

Chrys kokinoNuvan dassanaikePharmaceuticals onIntas pharmaceuticals ltdDrug administrationIntas pharmaceuticalsNew drug applicationForesee pharmaceuticalsAccord biopharmaSafety informationVisit accordbiopharmaVice president digitalMarketing strategy

vimarsana © 2020. All Rights Reserved.